Abcam, ab8418, Anti-STK17A antibody

Size: 100µg
Rabbit Polyclonal STK17A antibody. Suitable for ICC, WB and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human STK17A aa 1-50.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Light chain type:unknown,
Carrier free:No,
Reacts with:Human,
Applications:ICC, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human STK17A aa 1-50. The exact immunogen used to generate this antibody is proprietary information.Q9UEE5,
Specificity:No reactivity to DRAK2, DAP or ZIP kinases.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2Preservative: 0.02% Sodium azideConstituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
STK17A also known as DRAK1 is a serine/threonine-protein kinase with a mass of approximately 45 kDa. This protein performs a role in cellular signal transduction by phosphorylating serine and threonine residues on target substrates. STK17A is expressed in a variety of human tissues with significant expression in the brain heart and skeletal muscle indicating its widespread regulatory functions.
Biological function summary
The kinase activity of STK17A affects processes like apoptosis and cell migration. It does not form a complex with other proteins but can directly interact with them to exert its influence. Through these interactions STK17A can regulate cell survival and death which are important in development and homeostasis within an organism.
Pathways
STK17A acts in the apoptosis signaling pathway and is known to modulate JNK (c-Jun N-terminal kinase) signaling. In the apoptosis pathway STK17A can modify the response of cells to stress stimuli effectively controlling programmed cell death. It shows functional association with proteins such as caspases which carry out the execution phase of apoptosis thereby linking STK17A to these essential cellular processes.
Dysregulation of STK17A has connections to cancer and neurodegenerative disorders. In cancer altered STK17A expression or activity can contribute to inappropriate cell survival and proliferation making it a relevant marker or target in tumor biology. It associates with proteins like Bcl-2 which are involved in promoting cell survival. In neurodegenerative disorders such as Alzheimer's disease changes in STK17A expression or function might affect neuronal apoptosis contributing to the pathology of these conditions.